argenx NV ADR (ARGX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $990.32 (-0.55%), Market cap $50.43B, P/E ratio 35.81, 52-week low–high $537.92 ~ $929.61.
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular
Financial statements, price targets, institutional (13F) holdings and related news for argenx NV ADR are updated in real time on BlackAll Trade.
argenx NV ADR trades at $990.32 (-0.55%). Real-time quotes and charts are available on BlackAll Trade.
argenx NV ADR has a market cap of about $50.43B. Its P/E ratio is 35.81.
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The compa